Marco Zaffagnini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marco Zaffagnini has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Burla
Department of Biomedical and Neuromotor Sciences—DIBINEM Alma Mater Studiorum University of Bologna Bologna Italy
1 shared publication Angelo Boffa
Clinica Ortopedica e Traumatologica II IRCCS Istituto Ortopedico Rizzoli Bologna Italy
1 shared publicationC. Musiani
Ortopedia e Traumatologia Rizzoli Argenta , Rizzoli Orthopaedic Institute , Argenta (FE) , Italy , ior.it
1 shared publicationCarola Cavallo
Laboratorio RAMSES, Dipartimento Rizzoli Research and Innovation Technology IRCCS Istituto Ortopedico Rizzoli Bologna Italy
1 shared publication- Eleonora Carillo
Clinica Ortopedica e Traumatologica II IRCCS Istituto Ortopedico Rizzoli Bologna Italy
1 shared publication Federico Raggi
Clinica Ortopedica e Traumatologica II IRCCS Istituto Ortopedico Rizzoli Bologna Italy
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2026 (1) , 2140595
Sequential Limb Lengthening: A Novel Staged Approach Combining External Fixation and a Motorized Intramedullary Lengthening Nail for a Large Posttraumatic Tibial Defect
Background: Managing large posttraumatic tibial defects presents significant challenges. External fixation is effective for distraction osteogenesis but has drawbacks, including prolonged treatment time and complications. Intramedullary lengthening nails improve patient comfort but have limitations in large bone transport. While combined techniques have been explored, to our knowledge a fully sequential approach where an external fixator is first used for distraction and then replaced by a motorized intramedullary lengthening nail continuing the lengthening has not been clearly described in the literature. This study presents a novel staged technique and a review of existing literature on limb lengthening strategies. Methods: We report the case of a 29‐year‐old male with a 16‐cm posttraumatic tibial defect, treated with 10 cm of bone transport using an external fixator, followed by 6 cm of additional lengthening with a motorized intramedullary nail. Additionally, a literature search was conducted in PubMed, Scopus, and Embase using keywords related to limb lengthening, external fixation, and intramedullary nailing. The technique and outcomes were compared with existing literature. Discussion: The review did not identify any studies on fully sequential limb lengthening. Most studies focus on pediatric cases or hybrid techniques where external fixation and intramedullary nailing are used simultaneously. Our sequential approach allowed for controlled distraction and successfully addressed a 16‐cm bone defect. Conclusions: This case highlights a previously undescribed staged limb lengthening approach. Sequential conversion from external fixation to a motorized intramedullary lengthening nail may offer advantages in reducing EFI, protecting neurovascular structures, and enhancing mechanical stability. Further research is needed to evaluate long‐term outcomes.
- 1 January 2026
- Published by Wiley in Case Reports in Orthopedics
- Vol. 2026 (1) , 2140595
Open AccessSequential Limb Lengthening: A Novel Staged Approach Combining External Fixation and a Motorized Intramedullary Lengthening Nail for a Large Posttraumatic Tibial Defect
Background: Managing large posttraumatic tibial defects presents significant challenges. External fixation is effective for distraction osteogenesis but has drawbacks, including prolonged treatment time and complications. Intramedullary lengthening nails improve patient comfort but have limitations in large bone transport. While combined techniques have been explored, to our knowledge a fully sequential approach where an external fixator is first used for distraction and then replaced by a motorized intramedullary lengthening nail continuing the lengthening has not been clearly described in the literature. This study presents a novel staged technique and a review of existing literature on limb lengthening strategies. Methods: We report the case of a 29‐year‐old male with a 16‐cm posttraumatic tibial defect, treated with 10 cm of bone transport using an external fixator, followed by 6 cm of additional lengthening with a motorized intramedullary nail. Additionally, a literature search was conducted in PubMed, Scopus, and Embase using keywords related to limb lengthening, external fixation, and intramedullary nailing. The technique and outcomes were compared with existing literature. Discussion: The review did not identify any studies on fully sequential limb lengthening. Most studies focus on pediatric cases or hybrid techniques where external fixation and intramedullary nailing are used simultaneously. Our sequential approach allowed for controlled distraction and successfully addressed a 16‐cm bone defect. Conclusions: This case highlights a previously undescribed staged limb lengthening approach. Sequential conversion from external fixation to a motorized intramedullary lengthening nail may offer advantages in reducing EFI, protecting neurovascular structures, and enhancing mechanical stability. Further research is needed to evaluate long‐term outcomes.
- Open Access
- 1 October 2025
- Published by Wiley in Journal of Experimental Orthopaedics
- Vol. 12 (4)
Micro‐fragmented adipose tissue for the treatment of hip osteoarthritis: A prospective pilot study at 1‐year follow‐up
Purpose: Micro‐fragmented adipose tissue (MFAT) has been proposed as a promising option for hip osteoarthritis (OA). The aim of this prospective study was to evaluate clinical outcomes of MFAT injections in patients with hip OA. Methods: Thirty patients (19 men and 11 women, 55.7 ± 8.2 years) with symptomatic hip OA (Tönnis Grade 1–2) were treated with a single ultrasound‐guided MFAT injection. Patients were evaluated at baseline and 1–3–6–12 months of follow‐up with the Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), and Harris Hip Score (HHS). Adverse events were also documented. MFAT samples were evaluated for cell analysis and characterization. Results: No major complications were reported, and only three patients failed. The total WOMAC score significantly improved from baseline (31.2 ± 16.4) only at 1 month (21.0 ± 14.3, p = 0.015) and 3 months (19.3 ± 15.8, p = 0.012), while VAS and HHS scores showed a significant improvement from baseline to all follow‐ups. The minimal clinically important difference (MCID) for the total WOMAC score was achieved in 56.7% of patients at 6 and 12 months. Better clinical improvement and MCID achievement were observed in mild compared to moderate hip OA. A total of 300.000 cells derived from MFAT produced small colonies from Day 10 (89.9 ± 61.2), increasing by Day 20 (129.9 ± 47.9). Conclusions: A single ultrasound‐guided intra‐articular MFAT injection represents a safe and promising option for hip OA treatment. However, the clinical benefit was partial, and better outcomes were observed in mild compared to moderate hip OA. Level of Evidence: Level IV.
- 1 October 2025
- Published by Wiley in Journal of Experimental Orthopaedics
- Vol. 12 (4)
Open AccessMicro‐fragmented adipose tissue for the treatment of hip osteoarthritis: A prospective pilot study at 1‐year follow‐up
Purpose: Micro‐fragmented adipose tissue (MFAT) has been proposed as a promising option for hip osteoarthritis (OA). The aim of this prospective study was to evaluate clinical outcomes of MFAT injections in patients with hip OA. Methods: Thirty patients (19 men and 11 women, 55.7 ± 8.2 years) with symptomatic hip OA (Tönnis Grade 1–2) were treated with a single ultrasound‐guided MFAT injection. Patients were evaluated at baseline and 1–3–6–12 months of follow‐up with the Visual Analogue Scale (VAS), Western Ontario and McMaster Universities Arthritis Index (WOMAC), and Harris Hip Score (HHS). Adverse events were also documented. MFAT samples were evaluated for cell analysis and characterization. Results: No major complications were reported, and only three patients failed. The total WOMAC score significantly improved from baseline (31.2 ± 16.4) only at 1 month (21.0 ± 14.3, p = 0.015) and 3 months (19.3 ± 15.8, p = 0.012), while VAS and HHS scores showed a significant improvement from baseline to all follow‐ups. The minimal clinically important difference (MCID) for the total WOMAC score was achieved in 56.7% of patients at 6 and 12 months. Better clinical improvement and MCID achievement were observed in mild compared to moderate hip OA. A total of 300.000 cells derived from MFAT produced small colonies from Day 10 (89.9 ± 61.2), increasing by Day 20 (129.9 ± 47.9). Conclusions: A single ultrasound‐guided intra‐articular MFAT injection represents a safe and promising option for hip OA treatment. However, the clinical benefit was partial, and better outcomes were observed in mild compared to moderate hip OA. Level of Evidence: Level IV.